7 min. read

Blues’ verdict on PDTs: No. Pharma digital spin-offs.

Welcome back to E&O Fridays, a paying subscribers-only weekly newsletter focused on the world of digital pharma products and FDA-regulated digital health.

 E&O Fridays.

OK, here's what's happening this week in the world of pharma digital products and FDA-regulated digital health:

  • Cognito Therapeutics shared results from its Phase II study and plans to move onto its pivotal study for its prescription digital therapeutic for Alzheimer's. Here's more about the PhII. (Remember: This one is a Breakthrough device and since it runs on its own hardware, it's likely a lay-up for the new MCIT reimbursement pathway.)
  • Mahana Therapeutics received a CE mark for its IBS-focused, prescription digital therapeutic, Parallel.
  • Empatica also received a CE mark for its wearable device, Aura, which certifies that it can detect and alert wearers to respiratory infections (including

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Recent Articles